Work

Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.4619

Authors: Avivit Peer, Maya Ish-Shalom, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, Roberto Pili, Natalie Maimon, Maya Gottfried, Henry Hayat, Svetlana Kovel, Avishay Sella, Avivit Neumann, Ben Boursi, Raanan Berger, Michael Anthony Carducci, Daniel Keizman

Institutions: Rambam Health Care Campus, Tel Aviv University, Meir Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Center, Wolfson Medical Center, Assaf Harofeh Medical Center, Sheba Medical Center

Language: English

Topic: Bone health and treatments

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4235365341

Cites:

Cited by:

Related to: 10